SCHEMBL3020122

SCHEMBL3020122

Cc1cc(S(=O)(=O)N2CCN(c3nc(Cc4ccc(F)c(Cl)c4)cs3)CC2)c(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
TP53 P04637 1/20 0.37
SOS1 Q07889 2/20 0.37
LPAR1 Q92633 1/20 0.36
LPAR2 Q9HBW0 1/20 0.36
MAPK1 P28482 1/20 0.36
ENPP2 Q13822 2/20 0.36
GLA P06280 1/20 0.36
RAB9A P51151 1/20 0.36
CHRM5 P08912 1/20 0.35
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018624 0.95 CACNA1G (0.38) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3021475 0.93 LMNA (0.38) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3013845 0.92 LMNA (0.39) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3016084 0.91 LMNA (0.40) LMNAL3MBTL1MAPTMEN1KMT2A
SCHEMBL3002366 0.90 LMNA (0.39) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3010728 0.89 LMNA (0.40) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3018847 0.89 SOS1 (0.37) LMNAMAPTCNR1CNR2SOS1
SCHEMBL3654787 0.88 SMN1; SMN2 (0.35) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3009882 0.88 CNR1 (0.42) LMNASMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3653419 0.88 CNR1 (0.39) LMNAL3MBTL1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.